Literature DB >> 15886795

B-domain deleted factor VIII is aggregated and degraded through proteasomal and lysosomal pathways.

Jean-Luc Plantier1, Benoit Guillet, Cécile Ducasse, Nathalie Enjolras, Marie-Hélène Rodriguez, Véronique Rolli, Claude Négrier.   

Abstract

Factor VIII (FVIII) processing within mammalian cells is demonstrated to be much less efficient than proteins of similar size. The deletion of the B-domain from FVIII improves the level of production, due partly to the increase in mRNA synthesis. We aimed to characterise the cellular fate and the intracellular processing of the FVIII molecule devoid of B-domain. A B-domain deleted factor VIII (BDD-FVIII) possessing a furin consensus cleavage site in the connecting segment between the heavy and the light chain, was produced in CHO cell line. In such cells, FVIII was retained as two single chain products from which a majority was aggregated. The two species were located in Triton X-100 soluble (for 60-80%) and insoluble fractions (for 20-40%). The incubation of the expressing cells with tunicamycin (5 mug/ml) and the treatment of the intracellular species with a mixture of Neuraminidase and N-glycosidase-F revealed that both intracellular species were N-glycosylated. Furin over-expression neither diminished the intracellular FVIII contents nor improved its extracellular production. Intracellular FVIII was degraded through both lysosomal and proteasomal pathways as evidenced by inhibitor treatments (e.g. NH(4)Cl, leupeptin, clasto-Lactacystin beta-lactone and MG-132), pulse-chase analysis and confocal observations. This study demonstrates that a BDD-FVIII expressed in CHO cells is inefficiently processed consecutively to intracellular aggregation, proteasomal degradation, and routage to lysosomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886795     DOI: 10.1160/TH04-09-0579

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Expression of human coagulation factor VIII in a human hybrid cell line, HKB11.

Authors:  Baisong Mei; Yaoqi Chen; Jianmin Chen; Clark Q Pan; John E Murphy
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

2.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

3.  Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.

Authors:  Stefanie D Roth; Jörg Schüttrumpf; Peter Milanov; Daniela Abriss; Christopher Ungerer; Patricia Quade-Lyssy; Jeremy C Simpson; Rainer Pepperkok; Erhard Seifried; Torsten Tonn
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

4.  Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs.

Authors:  Jin Jea Sung; Chul-Yong Park; Joong Woo Leem; Myung Soo Cho; Dong-Wook Kim
Journal:  Exp Mol Med       Date:  2019-04-17       Impact factor: 8.718

5.  Cellular processing of myocilin.

Authors:  Ye Qiu; Xiang Shen; Rajalekshmy Shyam; Beatrice Y J T Yue; Hongyu Ying
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

Review 6.  Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.

Authors:  Benjamin J Samelson-Jones; Valder R Arruda
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-31       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.